Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease
Summary
- Switching to an integrase inhibitor to manage dyslipidemia appears attractive given the favorable metabolic profile of these agents in therapy-naive patients[Quercia 2015; Sierra-Madero 2010; Lennox 2010; Gallant 2017; Sax 2017]
- Lipid parameters significantly improved in virologically suppressed patients who switched from a boosted PI to coformulated bictegravir/emtricitabine/tenofovir AF in Study 1878[Daar 2017]
- Switching from a fully suppressive 3-drug regimen to the 2-drug regimen of dolutegravir/rilpivirine was associated with minimal effects on lipids and cardiovascular biomarkers[Llibre 2018]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content